FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Risa Tanaka

Research Profile

Anatomy

Chemicals & Drugs

Physiology

Procedures

Antineoplastic Combined Chemotherapy Protocols

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Eishi Baba; Taito Esaki; Hiromitsu Fujishima; Hitoshi Kusaba; Akitaka Makiyama; Kenji Mitsugi; Shuji Nakano; Risa Tanaka; Keita Uchino; Koichi Akashi
Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients.
Hitoshi Kusaba; Taito Esaki; Kitaro Futami; Sinnosuke Tanaka; Hiromitsu Fujishima; Kenji Mitsugi; Kenji Sakai; Hiroshi Ariyama; Risa Tanaka; Naoko Kinugawa; Takashi Ueki; Rhuichi Mibu; Eishi Baba; Shuji Nakano; Koichi Akashi
Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
Eishi Baba; Hiromitsu Fujishima; Hitoshi Kusaba; Taito Esaki; Hiroshi Ariyama; Ken Kato; Risa Tanaka; Kenji Mitsugi; Yoshihiro Shibata; Mine Harada; Shuji Nakano
Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Risa Tanaka (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Eishi Baba; Taito Esaki; Hiromitsu Fujishima; Hitoshi Kusaba; Akitaka Makiyama; Kenji Mitsugi; Shuji Nakano; Risa Tanaka; Keita Uchino; Koichi Akashi
Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients.
Advances in therapy 2012;29(3):287-96.
2010: Hitoshi Kusaba; Taito Esaki; Kitaro Futami; Sinnosuke Tanaka; Hiromitsu Fujishima; Kenji Mitsugi; Kenji Sakai; Hiroshi Ariyama; Risa Tanaka; Naoko Kinugawa; Takashi Ueki; Rhuichi Mibu; Eishi Baba; Shuji Nakano; Koichi Akashi
Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
Cancer science 2010;101(12):2591-5.
2009: Eishi Baba; Hiromitsu Fujishima; Hitoshi Kusaba; Taito Esaki; Hiroshi Ariyama; Ken Kato; Risa Tanaka; Kenji Mitsugi; Yoshihiro Shibata; Mine Harada; Shuji Nakano
Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer.
Anticancer research 2009;29(5):1727-32.
2006: Baoli Qin; Hiroshi Ariyama; Eishi Baba; Risa Tanaka; Hitoshi Kusaba; Mine Harada; Shuji Nakano
Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Cancer chemotherapy and pharmacology 2006;58(5):577-84.
2006: Baoli Qin; Risa Tanaka; Yoshihiro Shibata; Shuji Arita; Hiroshi Ariyama; Hitoshi Kusaba; Eishi Baba; Mine Harada; Shuji Nakano
In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines.
Anti-cancer drugs 2006;17(4):445-53.
2006: Baoli Qin; Risa Tanaka; Hiroshi Ariyama; Yoshihiro Shibata; Shuji Arita; Hitoshi Kusaba; Eishi Baba; Mine Harada; Shuji Nakano
In-vitro differential metabolism and activity of 5-fluorouracil between short-term, high-dose and long-term, low-dose treatments in human squamous carcinoma cells.
Anti-cancer drugs 2006;17(4):439-43.
2006: Hiroshi Ariyama; Baoli Qin; Eishi Baba; Risa Tanaka; Kenji Mitsugi; Mine Harada; Shuji Nakano
Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells.
Journal of cellular biochemistry 2006;97(4):724-34.
2006: Baoli Qin; Ken Kato; Kenji Mitsugi; Minoru Nakamura; Risa Tanaka; Eishi Baba; Hiroshi Ariyama; Toshiro Kuroiwa; Mine Harada; Shuji Nakano
Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer.
Cancer chemotherapy and pharmacology 2006;57(1):114-9.
2005: Risa Tanaka; Hiroshi Ariyama; Baoli Qin; Yoshihiro Shibata; Yasushi Takii; Hitoshi Kusaba; Eishi Baba; Kenji Mitsugi; Mine Harada; Shuji Nakano
Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro.
Oncology reports 2005;14(3):683-8.
2005: Risa Tanaka; Yasushi Takii; Yoshihiro Shibata; Hiroshi Ariyama; Baoli Qin; Eishi Baba; Hitoshi Kusaba; Kenji Mitsugi; Mine Harada; Shuji Nakano
In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines.
Cancer chemotherapy and pharmacology 2005;56(3):279-85.
2005: Risa Tanaka; Hiroshi Ariyama; Baoli Qin; Yasushi Takii; Eishi Baba; Kenji Mitsugi; Mine Harada; Shuji Nakano
In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines.
Cancer chemotherapy and pharmacology 2005;55(6):595-601.
2004: Kenji Mitsugi; Tsuyoshi Nakamura; Norio Kashiwabara; Hiroshi Ariyama; Risa Tanaka; Eishi Baba; Minoru Nakamura; Mine Harada; Shuji Nakano
Protection against methotrexate toxicity by a soybean protein- and omega-3 fatty acid-containing diet: comparative study with a casein-containing diet.
Oncology reports 2004;12(1):41-5.
2003: Chizuko Hisano; Risa Tanaka; Hiromitsu Fujishima; Hiroshi Ariyama; Tanji Tsuchiya; Takashi Tatsumoto; Kenji Mitsugi; Minoru Nakamura; Shuji Nakano
Suppression of anoikis by v-Src but not by activated c-H-ras in human gallbladder epithelial cells.
Cell biology international 2003;27(5):415-21.